NASDAQ:TNYA Tenaya Therapeutics Q4 2025 Earnings Report $0.82 -0.05 (-5.52%) As of 03:09 PM Eastern This is a fair market value price provided by Massive. Learn more. ProfileEarnings HistoryForecast Tenaya Therapeutics EPS ResultsActual EPS-$0.12Consensus EPS -$0.12Beat/MissMet ExpectationsOne Year Ago EPSN/ATenaya Therapeutics Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/ATenaya Therapeutics Announcement DetailsQuarterQ4 2025Date3/11/2026TimeBefore Market OpensConference Call DateMonday, March 16, 2026Conference Call Time4:00PM ETUpcoming EarningsTenaya Therapeutics' Q2 2026 earnings is estimated for Wednesday, August 5, 2026, based on past reporting schedules, with a conference call scheduled on Friday, August 7, 2026 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Annual Report (10-K)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Annual report(10-K) Tenaya Therapeutics Earnings HeadlinesTenaya Therapeutics to Participate in the Jefferies Global Healthcare Conference 2026May 29, 2026 | globenewswire.comTenaya Therapeutics, Inc. (NASDAQ:TNYA) Receives Consensus Recommendation of "Moderate Buy" from AnalystsMay 28, 2026 | americanbankingnews.comHow to claim a stake in SpaceX before the June 12 IPOSpaceX is expected to go public on June 12 - and for the first time, everyday investors may have a way in before the IPO. Jeff Brown, who identified Bitcoin, Tesla, and Nvidia before gains as high as 52,400%, 2,150%, and 32,000% respectively, is sharing the details on how to claim a stake in Elon Musk's company before it hits public markets.June 2 at 1:00 AM | Brownstone Research (Ad)Analysts Offer Insights on Healthcare Companies: Tenaya Therapeutics (TNYA), Knight Therapeutics (OtherKHTRF) and TScan Therapeutics (TCRX)May 25, 2026 | theglobeandmail.comAnalysts Offer Insights on Healthcare Companies: ImmunityBio (IBRX) and Tenaya Therapeutics (TNYA)May 20, 2026 | theglobeandmail.comPositive Interim Data from Cohorts 1 and 2 of Tenaya’s RIDGE™-1 Phase 1b/2 Clinical Trial of TN-401 Demonstrated Consistent Reductions in Arrhythmia Burden for Adults with ...May 15, 2026 | markets.businessinsider.comSee More Tenaya Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Tenaya Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Tenaya Therapeutics and other key companies, straight to your email. Email Address About Tenaya TherapeuticsTenaya Therapeutics (NASDAQ:TNYA) is a clinical‐stage biotechnology company focused on the discovery and development of gene therapy solutions for cardiovascular diseases. Leveraging a proprietary adeno‐associated virus (AAV) platform, the company aims to deliver durable, one‐time treatments for patients suffering from genetic cardiomyopathies and other inherited heart disorders. Its research programs center on optimizing vector design, delivery methods and manufacturing processes to enhance tissue specificity and minimize immune responses. Founded in 2018 and headquartered in San Carlos, California, Tenaya has built a diversified pipeline of product candidates targeting conditions such as hypertrophic cardiomyopathy and other genetically driven forms of heart disease. The company’s lead programs are advancing through preclinical and early clinical stages, with a focus on establishing proof of concept in relevant patient populations. Research collaborations and strategic partnerships support Tenaya’s efforts to accelerate development timelines and expand its scientific capabilities. Tenaya operates primarily in the United States, where it maintains its main research and manufacturing facilities. The company also engages with regulatory authorities to shape the clinical development and eventual commercialization of its therapies. Its management team combines expertise in gene therapy, cardiovascular biology and biopharmaceutical development, positioning Tenaya to tackle the complex challenges of translating novel genetic medicines into practical treatments. With a commitment to addressing unmet needs in cardiovascular health, Tenaya Therapeutics seeks to transform the treatment landscape for patients with inherited heart diseases. By integrating advanced vector engineering with a deep understanding of cardiac biology, the company strives to deliver breakthrough therapies that offer long‐lasting benefits and improved quality of life.View Tenaya Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Dollar General Signals Reversal With 60% Rebound PotentialKohl's Stock Soars After Better-Than-Feared QuarterCredo Technologies Paved a Path to a $300 Price PointHubSpot Just Crushed the Bear Case—Is a Bigger Rally Ahead?5 Reasons to Pony Up for Pony AI Stock—and 1 Reason to WaitBraze Blazes Ahead on Q1 2027 Earnings Beat, Raised GuidanceDrone Stocks Soar As Pentagon Considers Funding, Including a Trump-Linked Name Upcoming Earnings Broadcom (6/3/2026)CrowdStrike (6/3/2026)Medtronic (6/3/2026)Ciena (6/4/2026)Oracle (6/10/2026)Adobe (6/11/2026)Accenture (6/18/2026)FedEx (6/23/2026)Micron Technology (6/24/2026)NIKE (6/30/2026) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
